Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

131 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis.
Taylor PN, Collins KS, Lam A, Karpen SR, Greeno B, Walker F, Lozano A, Atabakhsh E, Ahmed ST, Marinac M, Latres E, Senior PA, Rigby M, Gottlieb PA, Dayan CM; Trial Outcome Markers Initiative collaboration. Taylor PN, et al. Among authors: ahmed st. Lancet Diabetes Endocrinol. 2023 Dec;11(12):915-925. doi: 10.1016/S2213-8587(23)00267-X. Epub 2023 Nov 3. Lancet Diabetes Endocrinol. 2023. PMID: 37931637 Free article.
Expanding Treatment Options for Youth With Type 2 Diabetes: Current Problems and Proposed Solutions: A White Paper From the NICHD Diabetes Working Group.
Tamborlane WV, Haymond MW, Dunger D, Shankar R, Gubitosi-Klug R, Bethin K, Karres J, Tomasi P, Libman I, Hale PH, Portman R, Klingensmith G, Reed M, Blumer J, Giacoia G; NICHD Diabetes Working Group. Tamborlane WV, et al. Diabetes Care. 2016 Mar;39(3):323-9. doi: 10.2337/dc15-1649. Diabetes Care. 2016. PMID: 26908928 Free PMC article. No abstract available.
Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.
Battaglia M, Ahmed S, Anderson MS, Atkinson MA, Becker D, Bingley PJ, Bosi E, Brusko TM, DiMeglio LA, Evans-Molina C, Gitelman SE, Greenbaum CJ, Gottlieb PA, Herold KC, Hessner MJ, Knip M, Jacobsen L, Krischer JP, Long SA, Lundgren M, McKinney EF, Morgan NG, Oram RA, Pastinen T, Peters MC, Petrelli A, Qian X, Redondo MJ, Roep BO, Schatz D, Skibinski D, Peakman M. Battaglia M, et al. Diabetes Care. 2020 Jan;43(1):5-12. doi: 10.2337/dc19-0880. Epub 2019 Nov 21. Diabetes Care. 2020. PMID: 31753960 Free PMC article.
Erratum. Innovative Designs and Logistical Considerations for Expedited Clinical Development of Combination Disease-Modifying Treatments for Type 1 Diabetes. Diabetes Care 2022;45:2189-2201.
Anderson RL, DiMeglio LA, Mander AP, Dayan CM, Linsley PS, Herold KC, Marinac M, Ahmed ST. Anderson RL, et al. Among authors: ahmed st. Diabetes Care. 2022 Dec 1;45(12):3113. doi: 10.2337/dc22-er12a. Diabetes Care. 2022. PMID: 36219765 Free PMC article. No abstract available.
Baricitinib and β-Cell Function in Patients with New-Onset Type 1 Diabetes.
Waibel M, Wentworth JM, So M, Couper JJ, Cameron FJ, MacIsaac RJ, Atlas G, Gorelik A, Litwak S, Sanz-Villanueva L, Trivedi P, Ahmed S, Martin FJ, Doyle ME, Harbison JE, Hall C, Krishnamurthy B, Colman PG, Harrison LC, Thomas HE, Kay TWH; BANDIT Study Group. Waibel M, et al. N Engl J Med. 2023 Dec 7;389(23):2140-2150. doi: 10.1056/NEJMoa2306691. N Engl J Med. 2023. PMID: 38055252 Clinical Trial.
131 results